Chugai posts transcript of FY2026 Q2 financial results conference call

Reuters2026/07/27 08:54

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Chugai Pharmaceutical hosted its FY2026 Q2 results webcast July 24 with CEO Osamu Okuda, CFO Iwaaki Taniguchi, and other executives.
H1 revenue rose 14.7% to JPY 663.3 billion; core operating profit increased 21% to JPY 329.1 billion; full-year forecast maintained.
Management cited export growth led by Hemlibra; other revenue rose JPY 29.8 billion on one-time income, Hemlibra royalties, NEMLUVIO royalties.
NEMLUVIO momentum highlighted; Galderma reported H1 global sales of USD 433 million; Foundayo royalties began in Q2 following US obesity launch.
Pipeline updates included two Phase III starts for NXT007; AQUA07 first patient dosed; PiaSky aHUS filings targeted in Japan, US, Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chugai posts transcript of FY2026 Q2 financial results conference call

You may also like

Crypto prices